New Kidneys Do Not Tolerate Hypotension

“[T]he overarching message is difficult to ignore: hypotension burden tracks closely with delayed graft function.”Kidney transplantation occupies a uniquely fragile physiologic intersection: a newly implanted organ that has already endured ischemia–reperfusion injury is suddenly asked to function within the hemodynamic realities of major surgery. In this setting, even brief deviations in perfusion pressure may exact a disproportionate biological cost. The study by Delaporte et al.1 provides one of the most comprehensive examinations to date of whether intraoperative hypotension truly matters for early graft function, and their answer is both clear and clinically relevant. Using a rigorously curated cohort of more than 3,800 first-time kidney transplants over an 11-year period, the investigators demonstrated a dose–response association between the cumulative burden of hypotension and delayed graft function. By operationalizing hypotension as the area under the curve for mean arterial pressure (MAP) <65 mmHg, they captured both the depth and duration of intraoperative hypoperfusion: an approach that mirrors other studies in perioperative hemodynamics.2,3 Each additional 50 mmHg·min spent less than 65 mmHg translated into an 8% increase in the odds of delayed graft function—new kidneys do not like low pressure. The biologic plausibility of this association is compelling. The transplanted kidney arrives with endothelial dysfunction, microvascular congestion, and heightened susceptibility to oxidative stress and inflammatory injury.4,5 Autoregulation in this setting is impaired. What might be tolerable hypotension for native kidneys in nontransplant surgery becomes a direct ischemic insult for the graft. In this light, the findings of this study do not merely extend previous noncardiac surgery literature on intraoperative hypotension and acute kidney injury—they define a uniquely vulnerable population in which hypotension appears especially unforgiving. A particularly instructive feature of the analysis is the donor-stratified signal. Intraoperative hypotension was significantly associated with delayed graft function in deceased-donor recipients but not in living-donor transplants, where event rates were low. This divergence reinforces the concept that ischemia–reperfusion priming, organ quality, and cold ischemia time fundamentally modify hemodynamic vulnerability.6–8 In deceased-donor grafts, already metabolically stressed, additional perfusion deficits may push the kidney past a critical injury threshold. The study also contains a subtle yet natural experiment. Nearly a quarter of recipients did not receive hemodialysis on the day of surgery or the preceding day, allowing the authors to observe outcomes across patients likely entering the operating room with different volume states. Although subgroup analyses were not performed, the data invite the hypothesis that delayed dialysis, by preserving intravascular volume, might confer some degree of protection. Future work examining how volume status interacts with intraoperative blood pressure could clarify whether timing of preoperative dialysis should be tailored to hemodynamic risk rather than scheduling convenience. A central unresolved question remains: Is increased MAP synonymous with restored graft perfusion? Vasopressors increase pressure, but pressure is not flow. Because vasopressors may restore systemic MAP but not restore microvascular perfusion, especially in previously ischemic renal tissue, high-dose α-agonism could theoretically worsen microcirculatory oxygen delivery despite normal monitor values.9,10 Future studies on intrarenal perfusion/oxygenation in early graft reperfusion under different vasopressor regimens might provide additional insights. The authors acknowledge two limitations: First, the inability to distinguish hypotension occurring before versus after reperfusion may obscure distinct pathophysiologic phases. Second, postoperative hypotension could not be disentangled from intraoperative exposure.11 These gaps underscore the necessity for prospective, phase-resolved transplant-specific hemodynamic trials. Additionally, the authors focused their primary analysis on delayed graft function, but many transplant recipients carry heavy comorbidity burdens: heart failure, coronary disease, and diabetes. These organs do not sit idle during intraoperative hypotension. Expanding future analyses to composite outcomes, which include cardiac injury, neurologic events, and multiorgan dysfunction, may reveal that the vulnerability of the graft is only part of a wider physiological story. Despite these limitations, the overarching message is difficult to ignore: hypotension burden tracks closely with delayed graft function. Future investigation is warranted to examine whether maintaining a higher perioperative blood pressure could reduce delayed graft function. Taken together, this study delivers an important message: intraoperative hypotension is not merely a passenger in transplantation; it is a modifiable risk factor for graft injury. In a field where many determinants of delayed graft function are unmodifiable, donor quality, ischemic time, and immunologic risk, the ability to influence blood pressure is a rare opportunity. Transplant teams should treat intraoperative blood pressure with the same vigilance reserved for organ preservation and immunosuppression. After all, a new kidney, like any newly arrived guest, thrives when its environment is stable, generous, and well perfused. Research Support Shiqian Shen received support from NIH RF1AG070141, NIH R01AG082975, NIH R35GM128692, and NSF EAGER 2334666. Competing Interests The authors declare no competing interests.